Applying Fragment Drug Conjugates to Explore Novel Targets
Time: 1:30 pm
day: Conference Day Two
Details:
- Fine-tuning our FDC discovery platform to discover antibody fragments and linker payloads tailored for solid tumors
- Outlining the discovery of Antikor’s lead FDC program (ANT-045) and follow-up programs
- Reviewing the development of ANT-045 FDC in advanced models for tumor cure efficacy and safety
